このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

2018年7月26日 更新者：GlaxoSmithKline

Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.

The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.

In the extension phase, at Years 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This multicenter study is open and has 2 treatment groups with Hiberix™ + a commercially available MenC vaccine as active controls. Priorix™ is given concomitantly in both groups. In the primary phase, two blood samples are taken from all subjects for immunogenicity analyses: before and one month after vaccination. In the extension phase, at Year 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase.

研究の種類

介入

入学 (実際)

433

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • オーストラリア
    • Australian Capital Territory
      • Garran、Australian Capital Territory、オーストラリア、2606
        • GSK Investigational Site
    • New South Wales
      • Randwick、New South Wales、オーストラリア、2031
        • GSK Investigational Site
      • Westmead、New South Wales、オーストラリア、2145
        • GSK Investigational Site
    • Queensland
      • Herston、Queensland、オーストラリア、4029
        • GSK Investigational Site
    • South Australia
      • North Adelaide、South Australia、オーストラリア、5006
        • GSK Investigational Site
    • Victoria
      • Carlton、Victoria、オーストラリア、3053
        • GSK Investigational Site
    • Western Australia
      • Perth、Western Australia、オーストラリア
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年～1年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

Primary phase:

  • Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 18 months of age at the time of vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.
  • Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.

Long-term persistence phase:

- Having participated in the vaccination study 106445

Exclusion Criteria:

For the primary vaccination phase:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.
  • Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.
  • Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.
  • Previous administration of a booster dose of Hib vaccine.
  • Previous vaccination against measles, mumps, rubella.
  • History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.
  • Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of neurological disorders or more than one episode of febrile convulsion.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Additional exclusion criteria for the long-term persistence phase: to be checked each year.

  • Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.
  • History of H. influenzae type b, meningococcal serogroup C diseases.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：防止
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ：Meningitec + Hiberix Group
Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
生物学的：Priorix™
One subcutaneous dose at 12-18 months of age
生物学的：Hiberix™
One intramuscular dose at 12-18 months of age.
生物学的：Meningitec™
One intramuscular dose at 12-18 months of age
実験的：Menitorix Group
Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
生物学的：Priorix™
One subcutaneous dose at 12-18 months of age
生物学的：Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
One intramuscular dose at 12-18 months of age
他の名前：
  • Hib-MenC
  • Menitorix™

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
時間枠：1 month after vaccination
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.
1 month after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer
時間枠：1 month after vaccination
rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.
1 month after vaccination

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
時間枠：Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination

rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers.

Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
時間枠：5 years after vaccination
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
5 years after vaccination
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
時間枠：Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
時間枠：5 years after vaccination
Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
5 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
時間枠：Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
時間枠：5 years after vaccination
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
5 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
時間枠：Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Concentrations are given as Geometric Mean Concentrations (GMCs).
Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
時間枠：5 years after vaccination
Concentrations are given as Geometric Mean Concentrations (GMCs).
5 years after vaccination
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values
時間枠：Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Anti-polysaccharide C (Anti-PSC) Antibody Concentrations
時間枠：Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Concentrations given as Geometric Mean Concentrations (GMCs).
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Number of Subjects Reporting Solicited Local and General Symptoms
時間枠：Within 4 days (Day 0 -Day 3) after vaccination

Solicited local symptoms assessed include pain, redness and swelling at the injection site.

Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.
Within 4 days (Day 0 -Day 3) after vaccination
Number of Subjects Reporting Unsolicited Symptoms
時間枠：Within 31 days (Day 0 - Day 30) after vaccination
Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Within 31 days (Day 0 - Day 30) after vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs)
時間枠：Throughout the entire study period (up to year 5)

A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject.

For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.
Throughout the entire study period (up to year 5)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

GlaxoSmithKline

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2006年6月1日

一次修了 (実際)

2007年11月1日

研究の完了 (実際)

2007年11月6日

試験登録日

最初に提出

2006年5月12日

QC基準を満たした最初の提出物

2006年5月12日

最初の投稿 (見積もり)

2006年5月16日

学習記録の更新

投稿された最後の更新 (実際)

2018年8月24日

QC基準を満たした最後の更新が送信されました

2018年7月26日

最終確認日

2016年9月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • 106445
  • 106446 (その他の識別子：GSK)
  • 106449 (その他の識別子：GSK)
  • 106450 (その他の識別子：GSK)
  • 106452 (その他の識別子：GSK)
  • 106454 (その他の識別子：GSK)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

試験データ・資料

  1. 統計分析計画
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register
  2. インフォームド コンセント フォーム
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register
  3. 研究プロトコル
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register
  4. データセット仕様
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register
  5. 個人参加者データセット
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register
  6. 臨床研究報告書
    情報識別子：106445
    情報コメント：For additional information about this study please refer to the GSK Clinical Study Register

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する